Compound Evidence File
#EC-2026-0350
Adamax
Filed under Peptides. The bureau holds 148 laboratory returns for this compound from 40 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.
Cross-Index
Subjects Shipping This Compound
40 SUBJECTS| Subject | Grade | Samples | Mean | Min | Max | First seen | Last seen |
|---|---|---|---|---|---|---|---|
| Kerui PeptidesCASE #VI-2026-0626 | A | 4 | 10.0 | 9.9 | 10.0 | 17 Feb 2026 | 9 Jul 2026 |
| Flourishglobal PeptideCASE #VI-2026-0630 | A | 4 | 10.0 | 9.9 | 10.0 | 15 Jan 2026 | 23 Jun 2026 |
| Thermo Fisher ScientificCASE #VI-2026-0142 | A | 4 | 10.0 | 9.9 | 10.0 | 25 May 2026 | 14 Aug 2026 |
| Shanghai ERP BiotechnologyCASE #VI-2026-0936 | A | 3 | 10.0 | 10.0 | 10.0 | 13 Mar 2026 | 3 Jul 2026 |
| Chinese Peptide CompanyCASE #VI-2026-0184 | A | 3 | 10.0 | 9.9 | 10.0 | 6 May 2026 | 12 Jul 2026 |
| AsymchemCASE #VI-2026-0091 | A | 3 | 10.0 | 10.0 | 10.0 | 18 Jun 2026 | 2 Jul 2026 |
| AmbioPharmCASE #VI-2026-0177 | A | 3 | 10.0 | 9.9 | 10.0 | 11 May 2026 | 9 Jul 2026 |
| QYAOBIOCASE #VI-2026-0861 | A | 2 | 10.0 | 10.0 | 10.0 | 12 Mar 2026 | 13 May 2026 |
| Mokemei BiotechnologyCASE #VI-2026-0540 | A | 2 | 10.0 | 10.0 | 10.0 | 24 Apr 2026 | 17 May 2026 |
| Tianjin Finder Chemical TFCCASE #VI-2026-0693 | A | 5 | 9.9 | 9.9 | 10.0 | 14 Nov 2025 | 16 Apr 2026 |
| HomopeptideCASE #VI-2026-0760 | A | 4 | 9.9 | 9.9 | 10.0 | 23 May 2026 | 23 May 2026 |
| JEEP PeptidesCASE #VI-2026-0457 | A | 4 | 9.9 | 9.9 | 10.0 | 14 Mar 2026 | 1 Jul 2026 |
| BachemCASE #VI-2026-0314 | A | 4 | 9.9 | 9.9 | 9.9 | 15 Mar 2026 | 6 Jun 2026 |
| Hubei JianxiangCASE #VI-2026-0048 | A | 4 | 9.9 | 9.9 | 10.0 | 16 Nov 2025 | 23 Jun 2026 |
| Shanghai Wibson BiotechnologyCASE #VI-2026-0379 | A | 4 | 9.9 | 9.9 | 10.0 | 5 Dec 2025 | 19 Jun 2026 |
| WuXi TIDESCASE #VI-2026-0335 | A | 4 | 9.9 | 9.9 | 10.0 | 2 Mar 2026 | 8 Jun 2026 |
| Hybio PharmaceuticalCASE #VI-2026-0065 | A | 4 | 9.9 | 9.9 | 10.0 | 1 Jul 2026 | 20 Jul 2026 |
| GenScript PeptidesCASE #VI-2026-0860 | A | 4 | 9.9 | 9.9 | 10.0 | 1 Jan 2026 | 10 Aug 2026 |
| PolyPeptide GroupCASE #VI-2026-0143 | A | 4 | 9.9 | 9.9 | 10.0 | 15 Dec 2025 | 19 Aug 2026 |
| SinoPepCASE #VI-2026-0387 | A | 3 | 9.9 | 9.9 | 9.9 | 2 Apr 2026 | 3 Aug 2026 |
| Sangon BioCASE #VI-2026-0671 | A | 2 | 9.9 | 9.9 | 10.0 | 26 Jan 2026 | 2 Jul 2026 |
| Shanghai Sigma AudleyCASE #VI-2026-0505 | A | 2 | 9.9 | 9.9 | 10.0 | 2 Mar 2026 | 23 Mar 2026 |
| Sigma-AldrichCASE #VI-2026-0829 | A | 2 | 9.9 | 9.9 | 9.9 | 8 Feb 2026 | 23 Jul 2026 |
| Qingdao Sigma Chemical QSCCASE #VI-2026-0538 | A | 7 | 9.0 | 8.1 | 10.0 | 24 May 2026 | 24 May 2026 |
| Pure Tested PeptidesCASE #VI-2026-0225 | X | 1 | 8.8 | 8.8 | 8.8 | 16 Mar 2025 | 16 Mar 2025 |
| Glbiochem (Shanghai)CASE #VI-2026-0704 | A | 7 | 8.7 | 6.4 | 9.8 | 24 May 2026 | 24 May 2026 |
| Shanghai Sigma Audley SSACASE #VI-2026-0486 | A | 8 | 8.6 | 7.8 | 10.0 | 24 May 2026 | 24 May 2026 |
| Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 | A | 2 | 8.6 | 7.2 | 9.9 | 23 May 2026 | 23 May 2026 |
| Hebei Rimao TechnologyCASE #VI-2026-0529 | X | 3 | 8.3 | 6.6 | 10.0 | 6 May 2025 | 17 May 2026 |
| Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 | A | 7 | 8.1 | 6.6 | 9.8 | 24 May 2026 | 24 May 2026 |
| Suaway Lab ResearchCASE #VI-2026-0488 | X | 1 | 7.8 | 7.8 | 7.8 | 13 Jun 2025 | 13 Jun 2025 |
| Heman Peptide HMCASE #VI-2026-0089 | X | 2 | 7.7 | 7.6 | 7.7 | 21 May 2025 | 26 Jan 2026 |
| Zztai PeptideCASE #VI-2026-0192 | C | 2 | 7.6 | 7.4 | 7.7 | 2 Apr 2025 | 21 May 2026 |
| Qing Li PeptideCASE #VI-2026-0469 | X | 8 | 7.5 | 5.7 | 10.0 | 3 Jun 2025 | 26 Jan 2026 |
| LiliPeptideCASE #VI-2026-0695 | X | 14 | 7.1 | 5.4 | 9.3 | 2 Apr 2025 | 17 May 2026 |
| Orbitrex PeptidesCASE #VI-2026-0812 | X | 1 | 7.1 | 7.1 | 7.1 | 24 Apr 2025 | 24 Apr 2025 |
| LN PeptidesCASE #VI-2026-0781 | X | 1 | 6.0 | 6.0 | 6.0 | 13 Feb 2025 | 13 Feb 2025 |
| Elite Research USACASE #VI-2026-0267 | X | 4 | 5.1 | 4.2 | 6.3 | 21 May 2025 | 23 May 2026 |
| Biolabshop LimitedCASE #VI-2026-0832 | X | 1 | 5.0 | 5.0 | 5.0 | 7 May 2025 | 7 May 2025 |
| Explicit SarmsCASE #VI-2026-0017 | X | 1 | 0.0 | 0.0 | 0.0 | 2 Apr 2025 | 2 Apr 2025 |
Open any subject to view the batch-level evidence for Adamax alone.